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ANSWERS
1. The differential diagnosis of genital ulcers includes herpetic
infection, syphilis, chancroid or inguinal granulomata. Genital
herpes simplex virus usually causes grouped vesicular lesions
over an erythematous base. Superficial ulceration and regional
lymph nodes are common [1]. Syphilitic chancroid consists of a
painless ulcer with bilateral lymphadenopathy. Chancroid [2],
which is caused by Hemophilus ducreyi, usually presents as soft,
painful, necrotic ulcers. Half of the patients may have inguinal
lymph nodes, which may become fluctuant and even fistulize.
Culture sensitivity reaches 80%. Inguinal granulomata is usually
present in India and South America and presents as destructive
painless ulcers with tissue formation. None of these findings was
present in our patient.
Skin lesions in immunocompromised patients may be caused
by different microorganisms, including Staphylococcus aureus,
Pseudomonas aeruginosa, Aeromonas hydrophila, Vibrio spp., Candida
spp., Cryptococcus neoformans, Trichosporon spp., Aspergillus spp. or
Zygomycetes spp. Many of them may cause similar lesions.
Cutaneous lesions caused by Candida [3] consist of folliculitis
or erythematous macula or papules, which may be confluent
and sometimes pruritic. Up to 10–15% of patients with dis-
seminated cryptococcosis may have skin involvement, which
may present as papules, pustules, nodules, ulcers or verrucas [4].
Mucosal involvement is uncommon. Invasive aspergillosis may
also cause necrotizing ulcers, cutaneous nodules or papules [5],
usually with lung infiltrates. Accordingly, the isolation of
the microorganism is essential for establishing the diagnosis.
The chosen diagnostic technique in this case was a biopsy of
the ulcer.
2. Septate hyphae were seen in the histologic section of
the lesion, and Fusarium sp. was recovered from the ulcer.
Liposomal amphotericin B was administered (5 mg/kg/day),
reaching a total dose of 5 g. Both the ulcer and the lung
lesions completely resolved. Tolerance to the therapy was
excellent.
Infection caused by Fusarium in neutropenic patients has
many similarities to aspergillosis. Both share paranasal sinus
and lung as portals of entry in most cases. Lung lesions may
appear as alveolar infiltrates or as nodules that may cavitate. The
most common symptoms include persistent fever refractory to
broad-spectrum antimicrobials and even to antifungal agents in
a severely neutropenic patient [6]. However, skin lesions are
more common in disseminated fusariosis (60–80%) than in
aspergillosis. They may appear as cellulitis, onycomycosis,
subcutaneous nodules or ectima gangrenosum-like lesions.
Histology usually shows vascular invasion, with septate
hyphae branching at acute angles which cannot be differentiated
from those of Aspergillus. They may be difficult to identify with
hematoxylin and eosin stain, so silver or Schiff stains are
preferred. Definitive diagnosis lies in the recovery of the
microorganisms from tissue or blood cultures, which may be
positive in up to 40–50% [6]. Histopathologic or PCR tech-
niques may be helpful in the diagnosis [7].
Microbiologically, direct examination of the sample shows
hyaline septate hyphae (3–6 mm wide), quite similar to those of
Aspergillus or Scedosporium. Dicotomic branching is the rule,
sometimes with narrowing at the base. Fusarium grows well in
most fungal media, although the type of culture medium may
influence the color of the colonies and the production of
conidia. Enriched media may avoid macroconidia expression.
3. The optimal therapy for disseminated fusariosis has not
been established. Most patients are reported to have been
treated with amphotericin B [8]. However, many of these
isolates are resistant in vitro to this antifungal (18/23 strains
studied from 1997 to 1999 by our national reference center—
Centro Nacional de Majadahonda).
Neither fluconazole nor itraconazole are active against this
microorganism, although new triazoles, such as voriconazole or
posaconazole have shown activity against it both in vitro and in
vivo [9]. In vitro data cannot be considered to be predictive of
the clinical response of Fusarium infections, and the recovery of
the granulocyte count seems to be the essential factor. The use
of granulocyte or macrophage colony-stimulating factors seems
to have a favorable impact on survival, although more data are
needed before its use can be routinely recommended. The
overall mortality of disseminated fusariosis ranges between 50
and 80%, and may reach 100% in persistently neutropenic
patients [10–13].
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